Search
-
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection
Media
International AIDS Society Conference on HIV Science demonstrate non-inferior efficacy of Dovato▼ in virally suppressed adults with HIV
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/
First published: 24 July 2019
-
GlaxoSmithKline update: influenza A (H1N1)
Media
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/
First published: 30 April 2009
-
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
Media
ViiV today announced that the US FDA has approved Rukobia (fostemsavir), 600 mg extended-release tablets.
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/
First published: 02 July 2020
-
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Media
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/
First published: 17 December 2020
-
GlaxoSmithKline update: A (H1N1) influenza vaccine development
Media
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/
First published: 14 May 2009
-
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
Media
GSK & Enigma have signed agreements to develop and supply influenza tests to identify virus strains using its real-time PCR technology.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/
First published: 20 July 2009
-
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
Media
Shionogi-ViiV announced phase III data required for initial regulatory filings of dolutegravir in adults infected with HIV are in house.
https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/
First published: 04 October 2012
-
Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine
Media
Licences should enable potentially millions of people living in areas most impacted by HIV to access innovative prevention medicine.
https://www.gsk.com/en-gb/media/press-releases/medicines-patent-pool-signs-sublicences-with-aurobindo-cipla-and-viatris-to-produce-generic-versions-of-viiv-healthcare-s-innovative-long-acting-hiv-prevention-medicine/
First published: 30 March 2023
-
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
Media
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca for treatment of virologically suppressed adults with HIV
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/
First published: 03 April 2019
-
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis
Media
INSPIRING study results contribute to extensive body of evidence for dolutegravir
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/
First published: 05 March 2018